Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The shrinking renal replacement therapy "break-even" point

E J Schweitzer1, A Wiland, D Evans

  • 1Department of Surgery, University of Maryland, Baltimore, USA. gschweitzer@surgery1.umaryland.edu

Transplantation
|January 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Double-Blind, Double-Dummy, Flexible-Design Randomized Multicenter Trial: Early Safety of Single- Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Similar results with solitary pancreas transplantation compared with simultaneous pancreas-kidney transplantation in the new millennium.

Transplantation proceedings·2014
Same author

5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.

Transplantation proceedings·2014
Same author

A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients.

Clinical transplantation·2013
Same author

Efficiency of the LigaSure vessel sealing system for recipient hepatectomy in liver transplantation.

Transplantation proceedings·2013
Same journal

Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.

Transplantation·2026
Same journal

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same journal

People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

Transplantation·2026
Same journal

IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

Transplantation·2026
Same journal

Regulatory T Cells Allosensitized Under the Blockade of CD80/CD86-CD28 Costimulation Prolonged Islet Allograft Survival.

Transplantation·2026
Same journal

Desensitization With Tocilizumab and IVIg: A Prospective Controlled Cohort Study in a Predominantly Black American Population.

Transplantation·2026
See all related articles

Reducing live donor kidney transplant costs is possible through early discharge and avoiding routine immunosuppression. This approach makes transplants more cost-effective than dialysis within two years.

Area of Science:

  • Nephrology
  • Transplant Surgery
  • Health Economics

Background:

  • Live donor (LD) kidney transplantation is a vital treatment option.
  • The financial implications of LD transplantation compared to dialysis require ongoing evaluation.
  • Optimizing cost-effectiveness in transplantation is crucial for patient access and healthcare resource allocation.

Purpose of the Study:

  • To assess the current cost of live donor kidney transplantation at our institution.
  • To compare the costs of LD transplantation with the costs of dialysis.
  • To identify strategies for reducing the financial burden of LD kidney transplants.

Main Methods:

  • Analysis of 184 adult recipients of laparoscopic LD kidney transplants.
  • Implementation of cost-containment measures: no routine anti-lymphocyte induction and an accelerated discharge pathway (POD 2).

Related Experiment Videos

  • Estimation of transplant costs to Medicare using hospital charges, readmission rates, and immunosuppressant use; comparison with dialysis costs.

    • Main Results:

    • High 1-year patient (97%) and graft (93%) survival rates.
    • Low acute rejection rates with no induction: 27.6% (cyclosporine-MMF) and 13.9% (tacrolimus-MMF).
    • Accelerated discharge pathway resulted in lower mean hospital charges and a 16% 30-day readmission rate for early discharges.

    Conclusions:

    • Routine postoperative anti-lymphocyte immune induction can be safely eliminated to reduce LD transplant costs.
    • An early discharge clinical pathway significantly lowers hospital charges and maintains low readmission rates.
    • Uncomplicated LD kidney transplants become more cost-effective than dialysis within two years.